Skip to content

Merck’s Talks to Acquire Seagen Hit Snag Over Price

  • Seagen deal would be biggest for Merck in more than a decade
  • Talks could still resume and and possibly lead to agreement
Updated on

Merck & Co.’s talks to buy cancer-drug maker Seagen Inc. have stalled for now, threatening what would be the pharmaceutical giant’s biggest deal in more than a decade, according to people familiar with the matter.

The companies have so far failed to agree on a price, said the people, who asked not to be identified because the information was private. The talks could still resume and possibly yield an agreement, the people said. Seagen shares fell 8.6% at 9:32 am. in New York.